



NDA 22-214

NDA APPROVAL

AstraZeneca Pharmaceuticals LP
Attention: E. Jane Valas, Ph.D.
Associate Director, Regulatory Affairs
1800 Concord Pike, P.O. Box 8355
Wilmington, DE 19803-8355

Dear Dr. Valas:

Please refer to your new drug application (NDA) dated September 4, 2007, received September 5, 2007, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Arimidex (anastrozole) Tablets, 1 mg.

We acknowledge receipt of your submissions dated September 5, November 26, December 21, 26, 2007, and February 13 and September 10, 2008.

This new drug application was submitted in response to the Pediatric Written Request issued on April 8, 2005. It provides for the addition of safety, efficacy and pharmacokinetic information for Arimidex in the pediatric population, specifically male pubertal patients with gynecomastia and female pediatric patients with McCune-Albright syndrome with progressive precocious puberty, to the Pediatric Use section of the labeling.

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling text.

We are waiving the requirements of 21 CFR 201.57(d)(8) regarding the length of Highlights of prescribing information. This waiver applies to all future supplements containing revised labeling unless we notify you otherwise.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, please submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format as described at <http://www.fda.gov/oc/datacouncil/spl.html> that is identical to the enclosed labeling (text for the package insert, text for the patient package insert) submitted on November 4, 2008, to NDA 20-541. Upon receipt, we will transmit that version to the National Library of Medicine for public dissemination. For administrative purposes, please designate this submission, "SPL for approved NDA 22-214."

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

We note that you have fulfilled the pediatric study requirement for ages 11 through 18 years in male pubertal patients with gynecomastia and for ages 3 through 11 years in female pediatric patients with McCune-Albright syndrome with progressive precocious puberty for this application.

We are waiving the pediatric study requirement for ages birth through less than 11 years in male pubertal patients with gynecomastia and for ages birth through less than 3 years and ages 11 through less than 18 years in female patients with McCune-Albright syndrome with progressive precocious puberty because studies in these age groups are either impracticable or not necessary.

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit, in triplicate, a cover letter requesting advisory comments, the proposed materials in draft or mock-up form with annotated references, and the package insert(s) to:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Drug Marketing, Advertising, and Communications
5901-B Ammendale Road
Beltsville, MD 20705-1266

As required under 21 CFR 314.81(b)(3)(i), you must submit final promotional materials, and the package insert(s), at the time of initial dissemination or publication, accompanied by a Form FDA 2253. For instruction on completing the Form FDA 2253, see page 2 of the Form. For more information about submission of promotional materials to the Division of Drug Marketing, Advertising, and Communications (DDMAC), see www.fda.gov/cder/ddmac.

LETTERS TO HEALTH CARE PROFESSIONALS

If you issue a letter communicating important safety related information about this drug product (i.e., a “Dear Health Care Professional” letter), we request that you submit an electronic copy of the letter to both this NDA and to the following address:

MedWatch
Food and Drug Administration
Suite 12B05
5600 Fishers Lane
Rockville, MD 20857

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

All 15-day alert reports, periodic (including quarterly) adverse drug experience reports, field alerts, annual reports, supplements, and other submissions should be addressed to the original NDA 20-541 for this drug product, not to this NDA. In the future, do not make submissions to this NDA except for the final printed labeling requested above.

If you have any questions, call Jennifer Johnson, Regulatory Project Manager, at (301) 796-2194.

Sincerely,

{See appended electronic signature page}

Mary H. Parks, M.D.
Director
Division of Metabolism and Endocrinology Products
Office of Drug Evaluation II
Center for Drug Evaluation and Research

Enclosure: Package Insert and Patient Package Insert

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Mary Parks
12/5/2008 05:31:56 PM